F. Su

发表

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Kam Y. J. Zhang, K. Flaherty, J. Sosman, 2010, Nature.

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.

D. Heimbrook, J. Grippo, B. Higgins, 2010, Cancer research.

FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973

N. van Bruggen, K. Hoeflich, Simon-Peter Williams, 2012, EJNMMI Research.

Efficacy of vemurafenib (V), a selective V600EBRAF inhibitor, as monotherapy or in combination with erlotinib (Erl) or erbitux (Erb) and irinotecan (Iri) doublets and triplets in a colorectal cancer (CRC) xenograft model.

Richard J Lee, B. Higgins, K. Kolinsky, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of vemurafenib (V), a selective V600Eb-raf inhibitor, as monotherapy or in combination with erlotinib (Erl) or erbitux (Erb) and irinotecan (Iri) doublets and triplets in a colorectal cancer (CRC) xenograft model.

D. Heimbrook, B. Higgins, K. Kolinsky, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.

S. Kopetz, Richard J Lee, D. Heimbrook, 2012, Cancer research.

Analysis of dermatologic events in vemurafenib-treated patients with melanoma.

A. Hauschild, D. Schadendorf, M. Lacouture, 2013, The oncologist.

Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.

Qiongqing Wang, K. Trunzer, Richard J Lee, 2012, Cancer research.

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

K. Flaherty, J. Reis-Filho, Qiongqing Wang, 2012, The New England journal of medicine.

First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors

J. Desai, J. Tabernero, M. Brown, 2016, Targeted Oncology.

Differences in the sonographic features of papillary thyroid microcarcinoma and nonmicrocarcinoma : a study of 279 patients

Chuang Chen, Shengrong Sun, Juan Wu, 2016 .

Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of (18) F-FDG-PET and (18) F-FLT-PET.

M. Bergström, S. Evers, O. Boerman, 2015, Contrast media & molecular imaging.

Plx4032, a selective b-rafV600E inhibitor has potent anti-tumor activity in b-rafV600E-bearing colorectal xenografts and shows additive effect with other chemoagents

C. Jianping, D. Heimbrook, K. Kolinsky, 2007 .

Antitumor Activity of Anti‐miR‐21 Delivered through Lipid Nanoparticles

Xiaobin B. Zhao, F. Su, Jing Li, 2022, Advanced Healthcare Materials.